Many standard nonimaging-based prediction tools exist for prostate cancer.
However, these tools may be limited in individual cases and need updating based on the improved understanding of the underlying complex biology of the disease and the emergence of the novel targeted molecular imaging methods. A new platform of automated predictive tools that combines the independent molecular, imaging, and clinical information can contribute significantly to patient care. Such a platform will also be of interest to regulatory agencies and payers as more emphasis is placed on supporting those interventions that have quantifiable and significant beneficial impact on patient outcome.
Written by:
Jadvar H. Are you the author?
Department of Radiology, Keck School of Medicine of USC, University of Southern California, 2250 Alcazar Street, CSC 102, Los Angeles, CA 90033, USA.
Reference: PET Clin. 2015 Apr;10(2):255-263.
doi: 10.1016/j.cpet.2014.12.007
PubMed Abstract
PMID: 25829090